Northwest Biotherapeutics OTC Stock Executives
| NWBO Stock | USD 0.27 0.01 3.85% |
Northwest Biotherapeutics employs about 19 people. The company is managed by 6 executives with a total tenure of roughly 25 years, averaging almost 4.0 years of service per executive, having 3.17 employees per reported executive. Analysis of Northwest Biotherapeutics' management performance can provide insight into the firm performance.
| , MBA Insider Chief Officer |
| Leslie Goldman SVP Sr. VP of Bus. Devel. |
Northwest |
Northwest Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.2576) % which means that it has lost $1.2576 on every $100 spent on assets. This is way below average. Northwest Biotherapeutics' management efficiency ratios could be used to measure how well Northwest Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Northwest Biotherapeutics Workforce Comparison
Northwest Biotherapeutics is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 390. Northwest Biotherapeutics holds roughly 19.0 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of 52.11 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (54.95) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $54.95. Northwest Biotherapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Northwest Biotherapeutics Price Series Summation is a cross summation of Northwest Biotherapeutics price series and its benchmark/peer.
Northwest Biotherapeutics Notable Stakeholders
A Northwest Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Northwest Biotherapeutics often face trade-offs trying to please all of them. Northwest Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Northwest Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Leslie Goldman | Sr. VP of Bus. Devel. | Profile | |
| Alton Boynton | Founder, Chief Scientific Officer, Secretary and Director | Profile | |
| Linda JD | CEO, Chairperson | Profile | |
| David Innes | VP Relations | Profile | |
| Jean Davis | Chief Officer | Profile |
About Northwest Biotherapeutics Management Performance
The success or failure of an entity such as Northwest Biotherapeutics often depends on how effective the management is. Northwest Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Northwest management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Northwest management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.
The data published in Northwest Biotherapeutics' official financial statements typically reflect Northwest Biotherapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Northwest Biotherapeutics' quantitative information. For example, before you start analyzing numbers published by Northwest accountants, it's essential to understand Northwest Biotherapeutics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Northwest Biotherapeutics Workforce Analysis
Traditionally, organizations such as Northwest Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Northwest Biotherapeutics within its industry.Northwest Biotherapeutics Manpower Efficiency
Return on Northwest Biotherapeutics Manpower
| Revenue Per Employee | 52.9K | |
| Revenue Per Executive | 167.5K | |
| Net Income Per Employee | 9.4M | |
| Net Income Per Executive | 29.9M |
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.